摘要
目的根据现有临床研究系统评价甘草酸二铵治疗慢性乙型肝炎的疗效及安全性。方法从1995至2004年中国生物医学光盘数据库和1995至2004年中国期刊网数据库,检索以慢性乙型肝炎为研究对象,比较甘草酸二铵治疗与其他护肝药物治疗效果的随机对照试验(RCTs)文献,并对RCT进行meta荟萃分析。结果共24项RCT 3201例患者入选。甘草酸二铵组有效率高于对照组,两组比较差异有统计学意义(P<0.01);甘草酸二铵组有效率高于甘草酸单铵组,两组比较差异有统计学意义(P<0.01);甘草酸二铵联合丹参治疗慢性病毒性肝炎有明显抗纤维化功效。结论甘草酸二铵具有较强的护肝、退黄、抗肝纤维化等作用,未发现明显不良反应。
Objective In order to evaluate the efficacy of Diammonium Glycyrrhizinate in the treatment of chronic hepatitis B. Methods The randomized clinical trials (RCTs) that compared the efficacy of Diammonium Glycyrrhizinate and other kind of treatment in chronic hepatitis-B were chosen from CBM disks from 1995 to 2004 and CNKI from 1995 to 2004. A recta-analysis was employed to evaluate the results of these therapies. Results Twenty-four RCTs including 3201 cases were analyzed. Compared with control group, the total RR of efficiency rate of Diammonium Glycyrrhizinate group were 1.378(95%CI 1.243-1.529), showing significant difference (P〈0.01). There was significant difference between the efficiency rate of Diammonium Glycyrrhizinate group and that of Glycyrrhizin group——RR=1.273(95%CI 1.172-1.383),P〈0.01). Combining use of Diammonium Glycyrrhizinate and Danshen could exert better antifibrosis effect. Conclusions Diammonium Glycyrrhizinate was superior to both supportive drugs and Potenlini in treatment of chronic hepatitis-B. It could reduce ALT and TB and ameliorate fibrosis as well.
出处
《中华传染病杂志》
CAS
CSCD
北大核心
2005年第5期333-337,共5页
Chinese Journal of Infectious Diseases
关键词
甘草次酸
肝炎
乙型
慢性
Glycyrrhetinic acid
Hepatitis,B Chronic